Rockefeller Capital Management’s Oncolytics Biotech ONCY Stock Holding History

Rockefeller Capital Management’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.4K	Sell	10,939 -10,000	-48%	-$9.27K	﹤0.01%	4002
2026 Q1	$17.8K	Hold	20,939	–	–	﹤0.01%	3753
2025 Q4	$18.3K	Hold	20,939	–	–	﹤0.01%	3549
2025 Q3	$29.3K	Buy	+20,939	New	+$23.5K	﹤0.01%	3166
2023 Q1	–	Sell	-5,540	Closed	-$9K	–	3280
2022 Q4	$9K	Hold	5,540	–	–	﹤0.01%	3138
2022 Q3	$6K	Hold	5,540	–	–	﹤0.01%	3291
2022 Q2	$5K	Hold	5,540	–	–	﹤0.01%	3464
2022 Q1	$8K	Hold	5,540	–	–	﹤0.01%	3166
2021 Q4	$7K	Hold	5,540	–	–	﹤0.01%	3156
2021 Q3	$11K	Hold	5,540	–	–	﹤0.01%	2855
2021 Q2	$15K	Hold	5,540	–	–	﹤0.01%	2611
2021 Q1	$21K	Buy	5,540 +2,000	+56%	+$5.97K	﹤0.01%	2261
2020 Q4	$8K	Hold	3,540	–	–	﹤0.01%	2306
2020 Q3	$5K	Buy	3,540 +2,994	+548%	+$5.49K	﹤0.01%	2235
2020 Q2	$1K	Sell	546 -105	-16%	-$198	﹤0.01%	2479
2020 Q1	$1K	Hold	651	–	–	﹤0.01%	2297
2019 Q4	$3K	Buy	+651	New	+$735	﹤0.01%	1874

Other funds holding ONCY

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Seeds Investor New York $973M AUM 33.7% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return

Rockefeller Capital Management's ONCY Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Oncolytics Biotech (ONCY) stake by 48% in Q2 2026, selling an estimated $9.27K and leaving 10,939 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4002.

Rockefeller Capital Management first reported a position in ONCY in Q4 2019 and has held it in 17 quarters since. The position peaked at $29.3K in Q3 2025. 75 funds tracked by Wall St. Rank hold ONCY as of Q2 2026.

Rockefeller Capital Management held 10,939 shares of Oncolytics Biotech worth $10.4K as of Q2 2026.
Rockefeller Capital Management sold 10,000 Oncolytics Biotech shares in Q2 2026, an estimated $9.27K.
Oncolytics Biotech made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4002 holding.
Rockefeller Capital Management first reported a position in Oncolytics Biotech in Q4 2019 and has held it in 17 quarters since.
Rockefeller Capital Management's Oncolytics Biotech position peaked at $29.3K in Q3 2025.
75 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.